** Shares of drugmaker Vericel VCEL.O fall 12.7% to $51.25 in extended trading
** VCEL expects prelim Q4 revenue in the range of about $75.2 million to $75.7 million
** Analysts estimate Q4 revenue of $77.93 mln on average -data compiled by LSEG
** VCEL expects Q4 gross margin to be ~77% vs estimates of 75.43%
** Co expects 20% to 23% total revenue growth for 2025
** As of Dec 31, 2024, co had ~$167 million in cash, restricted cash and investments, and no debt - VCEL
** Up to last close, stock gained ~53% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。